All In Biotech

Drug Trial Radar · NCT05864144

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

May 31, 2023

Primary completion

Jun 2, 2026

Study completion Jun 2, 2026

Sponsor

Lead sponsor
Sensei Biotherapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
May 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Conditions

  • Solid Tumor, Adult
  • Advanced Solid Tumor
  • Head and Neck Cancer
  • Breast Cancer
  • Colon Cancer
  • Pancreatic Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Prostate Cancer
  • Uterine Cancer
  • Cervix Cancer
  • Ovarian Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Thyroid Cancer
  • Melanoma
  • Sarcoma
  • Advanced Cancer
  • Metastatic Cancer
  • Refractory Cancer
  • Non Small Cell Lung Cancer
  • Merkel Cell Carcinoma

Interventions

  • SNS-101 (anti-VISTA)Drug

    SNS-101 IV every 21 days.

  • CemiplimabDrug

    Cemiplimab IV every 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events - Part A & BTime frame: Day 1 through 90 days after the last dose
  2. Determine the Recommended Phase 2 dose or maximum tolerated dose - Part A & BTime frame: Approximately 15 months
  3. Objective Response Rate (ORR) - Part C. Part C was never initiated.Time frame: Day 1 through study completion (approximately 1 year).

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Hematology/Oncology

    Los Angeles, California

  • University of Colorado Cancer Center - Anschutz Medical

    Aurora, Colorado

  • Norton Healthcare

    Louisville, Kentucky

  • Henry Ford Cancer

    Detroit, Michigan

  • Icahn School of Medicine at Mt. Sinai

    New York, New York

  • University of Pennsylvania, Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Sanford Cancer Center

    Sioux Falls, South Dakota

  • NEXT Oncology Dallas

    Irving, Texas

  • South Texas Accelerated Research Therapeutics (START) San Antonio

    San Antonio, Texas

  • START Mountain Region

    West Valley City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.